Patents by Inventor Eva OBERMAYR

Eva OBERMAYR has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220145397
    Abstract: A method of identifying an SCLC patient at risk of disease progression comprising determining the expression of at least one marker selected from a neuroendocrine marker and/or DLLS in a blood sample or blood sample fraction of said patient, wherein said at least one marker is indicative of the patients prognosis.
    Type: Application
    Filed: March 2, 2020
    Publication date: May 12, 2022
    Inventors: Robert ZEILLINGER, Eva OBERMAYR, Gerhard HAMILTON
  • Publication number: 20120238458
    Abstract: A method of determining gynaecologic tumor disease in a subject by providing a sample of peripheral blood of the subject, measuring the PPIC expression of cells in the sample, and comparing this to a reference value, the PPIC overexpression being indicative of a gynecologic tumor disease and/or disease progression, including metastatic potential in a gynecologic cancer patient.
    Type: Application
    Filed: March 16, 2011
    Publication date: September 20, 2012
    Inventors: Dan CACSIRE CASTILLO-TONG, Dietmar PILS, Robert ZEILLINGER, Eva OBERMAYR
  • Publication number: 20110071032
    Abstract: A method of determining CCNE2 in a body fluid sample of patients at risk for solid tumor disease. A multi-marker panel is preferably used for detecting circulating tumor cells, comprising CCNE2, DKFZp762E1312, EMP2, MAL2, PPIC, SLC6A8 and GTF2IRD1, and optionally further comprising one or more markers from the group consisting of AGR2, FXYD3, S100A16, TFF1, mammaglobin A, FN, Epcam, tm4sf and rbpms.
    Type: Application
    Filed: September 15, 2010
    Publication date: March 24, 2011
    Inventors: Robert ZEILLINGER, Eva OBERMAYR, Dan CACSIRE CASTILLO-TONG